FDA sets November action date for enzalutamide

FDA assigned a PDUFA date of Nov. 22 for an NDA from Medivation Inc. (NASDAQ:MDVN) for enzalutamide to treat castration-resistant prostate cancer (CRPC) in patients previously treated with docetaxel. ...